Graham Lappin
Graham Lappin
GLappin Consulting and Educational
Verified email at
Cited by
Cited by
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
G Lappin, RC Garner
Nature reviews drug discovery 2 (3), 233-240, 2003
Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs
G Lappin, W Kuhnz, R Jochemsen, J Kneer, A Chaudhary, B Oosterhuis, ...
Clinical Pharmacology & Therapeutics 80 (3), 203-215, 2006
Sulforaphane and quercetin modulate PhIP–DNA adduct formation in human HepG2 cells and hepatocytes
JR Bacon, G Williamson, RC Garner, G Lappin, S Langouet, Y Bao
Carcinogenesis 24 (12), 1903-1911, 2003
Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability
G Lappin, Y Shishikura, R Jochemsen, RJ Weaver, C Gesson, B Houston, ...
European journal of pharmaceutical sciences 40 (2), 125-131, 2010
Microdosing and drug development: past, present and future
G Lappin, R Noveck, T Burt
Expert opinion on drug metabolism & toxicology 9 (7), 817-834, 2013
The phase 0 microdosing concept
RC Garner, G Lappin
British journal of clinical pharmacology 61 (4), 367, 2006
The utility of microdosing over the past 5 years
G Lappin, RC Garner
Expert Opinion on Drug Metabolism & Toxicology 4 (12), 1499-1506, 2008
Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry
G Lappin, RC Garner
Analytical and bioanalytical chemistry 378 (2), 356-364, 2004
Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics
G Lappin, L Stevens
Expert Opinion on Drug Metabolism & Toxicology 4 (8), 1021-1033, 2008
The use of isotopes in the determination of absolute bioavailability of drugs in humans
G Lappin, M Rowland, RC Garner
Expert opinion on drug metabolism & toxicology 2 (3), 419-427, 2006
Microdosing and other phase 0 clinical trials: facilitating translation in drug development
T Burt, K Yoshida, G Lappin, L Vuong, C John, SN De Wildt, Y Sugiyama, ...
Clinical and translational science 9 (2), 74, 2016
The Application of Accelerator Mass Spectrometry to Absolute Bioavailability Studies in Humans: Simultaneous Administration of an Intravenous Microdose of 14C …
N Sarapa, PH Hsyu, G Lappin, RC Garner
The Journal of Clinical Pharmacology 45 (10), 1198-1205, 2005
Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human …
G Lappin, Y Shishikura, R Jochemsen, RJ Weaver, C Gesson, ...
European journal of pharmaceutical sciences 43 (3), 141-150, 2011
Radiotracers in drug development
G Lappin, S Temple
CRC Press, 2006
A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects
A Madan, Z O'Brien, J Wen, C O'Brien, RH Farber, G Beaton, P Crowe, ...
British journal of clinical pharmacology 67 (3), 288-298, 2009
The use of accelerator mass spectrometry to obtain early human ADME/PK data
G Lappin, RC Garner
Expert opinion on drug metabolism & toxicology 1 (1), 23-31, 2005
Positron emission tomography for use in microdosing studies.
CC Wagner, M Müller, G Lappin, O Langer
Current Opinion in Drug Discovery & Development 11 (1), 104-110, 2008
Biotransformation of monoterpenoids by suspension cultures of Lavandula angustifolia
GJ Lappin, JD Stride, J Tampion
Phytochemistry 26 (4), 995-997, 1987
Absolute oral bioavailability and metabolic turnover of β-sitosterol in healthy subjects
G Duchateau, B Cochrane, S Windebank, J Herudzinska, D Sanghera, ...
Drug Metabolism and Disposition 40 (10), 2026-2030, 2012
Comparative metabolism of 2, 4-dichlorophenoxyacetic acid (2, 4-D) in rat and dog
B Van Ravenzwaay, TD Hardwick, D Needham, S Pethen, GJ Lappin
Xenobiotica 33 (8), 805-821, 2003
The system can't perform the operation now. Try again later.
Articles 1–20